Skip to content

Comparison of Two Types of Shunts in Infants With Single Ventricle Defect Undergoing Staged Reconstruction--Pediatric Heart Network

Trial of Right Ventricular Versus Modified Blalock-Taussig Shunt in Infants With Single Ventricle Defect Undergoing Staged Reconstruction (A Trial Conducted by the Pediatric Heart Network)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00115934
Enrollment
555
Registered
2005-06-27
Start date
2005-05-31
Completion date
2009-10-31
Last updated
2025-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Defects, Congenital

Brief summary

This trial will evaluate the efficacy and safety of the modified Blalock-Taussig shunt (MBTS) compared to the right ventricle to pulmonary artery (RV-to-PA) shunt; compare the effect of the MBTS to that of the RV-to-PA shunt on the incidence of death or cardiac transplantation at 12 months post randomization; and compare the effect of the two shunts on intensive care unit (ICU) morbidity, unintended cardiovascular interventional procedures, right ventricular function, tricuspid valve regurgitation, pulmonary artery growth, and neurodevelopmental outcome.

Detailed description

BACKGROUND: Hypoplastic left heart syndrome (HLHS) and related single right ventricle anomalies are the highest risk congenital cardiovascular malformations. Surgical repair begins with the Norwood procedure during the newborn period, a stage II procedure at 4 to 6 months of age, and Fontan procedure at 18 to 36 months. The Norwood procedure remains one of the highest risk procedures in congenital heart surgery. A few small nonrandomized studies of a novel approach to the Norwood procedure have reported improved outcomes. This new approach uses a RV-to-PA shunt to provide pulmonary blood flow rather than the standard MBTS. This multi-center, randomized clinical trial will evaluate early and intermediate-term outcomes for patients undergoing a Norwood procedure with either the RV-to-PA shunt or the MBTS. This study has been approved by the Institutional Review/Research Ethics Boards of all participating clinical centers: Hospital for Sick Children, Toronto, Canada Children's Hospital Boston, Boston, MA Columbia College of Physicians and Surgeons, New York, NY Children's Hospital of Philadelphia, Philadelphia, PA Duke University Medical Center, Durham, NC Brody School of Medicine at East Carolina University, Greenville, NC Wake Forest Baptist Medical Center, Winston Salem, NC Medical University of South Carolina, Charleston, SC Children's Hospital of Wisconsin, Milwaukee, WI University of Michigan, Ann Arbor, MI Cincinnati Children's Hospital Medical Center, Cincinnati, OH Children's Hospital of Los Angeles, Los Angeles, CA Egleston Children's Hospital, Emory University, Atlanta, GA Congenital Heart Institute of Florida, University of South Florida, St. Petersburg, FL Alfred I. duPont Hospital for Children, Wilmington, DE DESIGN NARRATIVE: This is a prospective, randomized clinical trial of the RV-to-PA shunt versus MBTS in patients undergoing a Norwood procedure.

Interventions

PROCEDUREBlalock-Taussig pulmonary artery shunt

Performed at stage I palliative surgery for babies born with HLHS

PROCEDURERight ventricular to pulmonary artery shunt

Performed at stage I palliative surgery for babies born with HLHS

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
Pediatric Heart Network
CollaboratorOTHER
Carelon Research
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Diagnosis of hypoplastic left heart syndrome or related single, morphologic right ventricle anomaly * Planned Norwood procedure * Informed consent of parent(s) or legal guardian

Exclusion criteria

* Single, morphologic left ventricle anomaly * Preoperative identification of anatomy rendering either an MBTS or an RV-to-PA shunt technically impossible * Any major congenital abnormality (i.e., congenital diaphragmatic hernia, tracheoesophageal fistula) or acquired extra-cardiac disorder (e.g., meconium aspiration with need for high frequency ventilation, persistent renal failure requiring dialysis) that, in the opinion of the investigator, could independently affect the likelihood of the subject meeting the primary endpoint

Design outcomes

Primary

MeasureTime frameDescription
Proportion of Patients Who Died or Received a Heart TransplantMeasured at 12 monthsThe primary outcome was the proportion of patients who died or had cardiac transplantation 12 months after randomization.

Secondary

MeasureTime frameDescription
Echocardiographic Measures of Heart Size and Function: Right Ventricle (RV) End-diastolic Volume Indexed to Body Surface Area (BSA)Measured post-Norwood, an average of 17 days post-NorwoodRight ventricular end-diastolic volume indexed to BSA\^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.
Echocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSAMeasured pre-stage II surgery, an average of 15 days pre-stage II surgeryRight ventricular end-diastolic volume indexed to BSA\^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.
Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSAMeasured post-Norwood, an average of 17 days post-NorwoodRight ventricular end-systolic volume indexed to BSA. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.
Echocardiographic Measures of Heart Size and Function: RV Ejection FractionMeasured post-Norwood, an average of 17 days post-NorwoodRight ventricular ejection fraction: 100 x (RV end-diastolic volume - RV end-systolic volume)/RV end-diastolic volume. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.
Angiographic Findings: Left Pulmonary Artery SizeMeasured pre-stage II surgery, on average 26 days prior to stage II palliationDiameter of distal left pulmonary artery. Angiograms were performed at the time points relative to the second palliative surgery (pre-Stage II).
Proportion of Deaths or Heart Transplants Over Time From Randomization to the End of the TrialFrom Randomization to the End of the Trial, an average of 32 monthsThis secondary outcome was the proportion of deaths or cardiac transplantation over time from randomization to the end of the trial.
Unintended Cardiovascular Interventional ProceduresFrom Randomization to 12 monthsUnintended cardiovascular procedures included balloon dilation of the shunt or branch pulmonary arteries, stent placement in the shunt or branch pulmonary arteries, shunt revision, crossover between MBTS and RVPAS shunt, balloon dilation, stent placement or surgical revisions of the neo-aorta, and pulmonary artery reconstructions, other than those undertaken as a standard component of the stage II procedure. The number of cardiovascular procedures was analyzed; trial participants may have had more than one unintended cardiovascular. procedure.
Complications: Total Number Experienced During Norwood HospitalizationNorwood Hospitalization, an average of 36 daysComplications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.
Complications: Total Number Experienced From Norwood Discharge to Stage II DischargeFrom Norwood Discharge to Stage II discharge, an average of 4.2 monthsComplications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.
Complications: Total Number Experienced From Stage II Discharge to 14 Months of AgeFrom Stage II Discharge to 14 Months of Age, an average of 8.9 monthsComplications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.
Angiographic Findings: Right Pulmonary Artery SizeMeasured pre-stage II surgery, on average 26 days prior to stage II palliationDiameter of distal right pulmonary artery. Angiograms were performed at the time points relative to the second palliative surgery (pre-Stage II).

Countries

Canada, United States

Participant flow

Recruitment details

Subjects undergoing a Norwood were randomized to MBTS or RVPAS at 15 North American centers.

Pre-assignment details

There were no pre-assignment requirements beyond the initial screening criteria.

Participants by arm

ArmCount
MBTS
Blalock-Taussig pulmonary artery shunt
275
RVPAS
Right ventricular to pulmonary artery shunt
274
Total549

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyDid not receive intervention32
Overall StudyLost to Follow-up10

Baseline characteristics

CharacteristicMBTSRVPASTotal
Age, Categorical
<=18 years
275 Participants274 Participants549 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants
Age, Continuous5.1 days
STANDARD_DEVIATION 4.1
5.0 days
STANDARD_DEVIATION 4
5.1 days
STANDARD_DEVIATION 4
Region of Enrollment
Canada
7 participants8 participants15 participants
Region of Enrollment
United States
268 participants266 participants534 participants
Sex: Female, Male
Female
107 Participants102 Participants209 Participants
Sex: Female, Male
Male
168 Participants172 Participants340 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
249 / 275251 / 274
serious
Total, serious adverse events
146 / 275112 / 274

Outcome results

Primary

Proportion of Patients Who Died or Received a Heart Transplant

The primary outcome was the proportion of patients who died or had cardiac transplantation 12 months after randomization.

Time frame: Measured at 12 months

Population: 555 subjects were enrolled in the study; 5 of these subjects were excluded from analyses because a Norwood procedure was not performed; 1 subject was excluded because the subject withdrew before the 12-month follow-up, 12-month status was unknown. The data were analyzed on an intention to treat basis, subjects were analyzed as randomized.

ArmMeasureValue (NUMBER)
MBTSProportion of Patients Who Died or Received a Heart Transplant100 Participants
RVPASProportion of Patients Who Died or Received a Heart Transplant72 Participants
Comparison: The original sample size of 456 was based on 85% power, with a two-sided, two sample test of proportions (anticipating 28% MBTS subjects with events, 16% RVPAS subjects with events), and an alpha of 0.05. The critical p-value was 0.044 because four interim analyses were performed. The target trial size was increased from 466 to 554 to account for crossovers. The stopping boundary was crossed at the 4th interim look; however, the trial was not halted, because all subjects were enrolled.p-value: 0.01395% CI: [-17.8, -2.4]Fisher Exact
Secondary

Angiographic Findings: Left Pulmonary Artery Size

Diameter of distal left pulmonary artery. Angiograms were performed at the time points relative to the second palliative surgery (pre-Stage II).

Time frame: Measured pre-stage II surgery, on average 26 days prior to stage II palliation

Population: These patients had pre-stage II palliation visits with acceptable cardiac catheterizations.

ArmMeasureValue (MEAN)Dispersion
MBTSAngiographic Findings: Left Pulmonary Artery Size5.2 mmStandard Deviation 1.5
RVPASAngiographic Findings: Left Pulmonary Artery Size5.4 mmStandard Deviation 1.7
p-value: 0.54t-test, 2 sided
Secondary

Angiographic Findings: Right Pulmonary Artery Size

Diameter of distal right pulmonary artery. Angiograms were performed at the time points relative to the second palliative surgery (pre-Stage II).

Time frame: Measured pre-stage II surgery, on average 26 days prior to stage II palliation

Population: These patients had pre-stage II palliation visits with acceptable cardiac catheterizations.

ArmMeasureValue (MEAN)Dispersion
MBTSAngiographic Findings: Right Pulmonary Artery Size6.1 mmStandard Deviation 2
RVPASAngiographic Findings: Right Pulmonary Artery Size5.4 mmStandard Deviation 1.7
p-value: <0.001t-test, 2 sided
Secondary

Complications: Total Number Experienced During Norwood Hospitalization

Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.

Time frame: Norwood Hospitalization, an average of 36 days

ArmMeasureValue (NUMBER)
MBTSComplications: Total Number Experienced During Norwood Hospitalization850 complications
RVPASComplications: Total Number Experienced During Norwood Hospitalization792 complications
p-value: 0.2Poisson Regression
Secondary

Complications: Total Number Experienced From Norwood Discharge to Stage II Discharge

Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.

Time frame: From Norwood Discharge to Stage II discharge, an average of 4.2 months

Population: These numbers reflect those patients who were discharged from the hospital after the Norwood procedure and were transplant free.

ArmMeasureValue (NUMBER)
MBTSComplications: Total Number Experienced From Norwood Discharge to Stage II Discharge367 complications
RVPASComplications: Total Number Experienced From Norwood Discharge to Stage II Discharge515 complications
p-value: 0.002Poisson Regression
Secondary

Complications: Total Number Experienced From Stage II Discharge to 14 Months of Age

Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.

Time frame: From Stage II Discharge to 14 Months of Age, an average of 8.9 months

Population: These numbers reflect the number of patients who were discharged from the hospital after the Stage 2 procedure and were transplant-free.

ArmMeasureValue (NUMBER)
MBTSComplications: Total Number Experienced From Stage II Discharge to 14 Months of Age81 complications
RVPASComplications: Total Number Experienced From Stage II Discharge to 14 Months of Age145 complications
p-value: 0.03Poisson regression
Secondary

Echocardiographic Measures of Heart Size and Function: Right Ventricle (RV) End-diastolic Volume Indexed to Body Surface Area (BSA)

Right ventricular end-diastolic volume indexed to BSA\^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.

Time frame: Measured post-Norwood, an average of 17 days post-Norwood

Population: 241 and 239 patients remained in the MBTS and RVPAS groups at the time of the post-Norwood echo. Of these, some patients did not have acceptable echos or measures were not able to be obtained to calculate the volumes.

ArmMeasureValue (MEDIAN)
MBTSEchocardiographic Measures of Heart Size and Function: Right Ventricle (RV) End-diastolic Volume Indexed to Body Surface Area (BSA)91.2 ml/m^2.6
RVPASEchocardiographic Measures of Heart Size and Function: Right Ventricle (RV) End-diastolic Volume Indexed to Body Surface Area (BSA)86.5 ml/m^2.6
p-value: 0.09Wilcoxon (Mann-Whitney)
Secondary

Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction

Right ventricular ejection fraction: 100 x (RV end-diastolic volume - RV end-systolic volume)/RV end-diastolic volume. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.

Time frame: Measured pre-stage II surgery, an average of 15 days pre-stage II surgery

Population: 181 and 214 patients remained in the MBTS and RVPAS groups at the time of the pre-Stage II echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.

ArmMeasureValue (MEAN)Dispersion
MBTSEchocardiographic Measures of Heart Size and Function: RV Ejection Fraction42.9 Percentage of RV end-diastolic volumeStandard Deviation 7.9
RVPASEchocardiographic Measures of Heart Size and Function: RV Ejection Fraction44.7 Percentage of RV end-diastolic volumeStandard Deviation 8.3
p-value: 0.07t-test, 2 sided
Secondary

Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction

Right ventricular ejection fraction: 100 x (RV end-diastolic volume - RV end-systolic volume)/RV end-diastolic volume. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.

Time frame: Measured at 14 months of age

Population: 184 and 179 patients remained in the MBTS and RVPAS groups at the 14-months of age echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.

ArmMeasureValue (MEAN)Dispersion
MBTSEchocardiographic Measures of Heart Size and Function: RV Ejection Fraction42.7 Percentage of RV end-diastolic volumeStandard Deviation 7.4
RVPASEchocardiographic Measures of Heart Size and Function: RV Ejection Fraction42.7 Percentage of RV end-diastolic volumeStandard Deviation 8
p-value: 0.97t-test, 2 sided
Secondary

Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction

Right ventricular ejection fraction: 100 x (RV end-diastolic volume - RV end-systolic volume)/RV end-diastolic volume. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.

Time frame: Measured post-Norwood, an average of 17 days post-Norwood

Population: 241 and 239 patients remained in the MBTS and RVPAS groups at the time of the post-Norwood echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes used to calculate the ejection fraction.

ArmMeasureValue (MEAN)Dispersion
MBTSEchocardiographic Measures of Heart Size and Function: RV Ejection Fraction44.5 Percentage of RV end-diastolic volumeStandard Deviation 7.6
RVPASEchocardiographic Measures of Heart Size and Function: RV Ejection Fraction48.5 Percentage of RV end-diastolic volumeStandard Deviation 7.6
p-value: <0.001t-test, 2 sided
Secondary

Echocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA

Right ventricular end-diastolic volume indexed to BSA\^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.

Time frame: Measured at 14 months of age

Population: 184 and 179 patients remained in the MBTS and RVPAS groups at the 14-months of age echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.

ArmMeasureValue (MEDIAN)
MBTSEchocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA83.3 ml/m^2.6
RVPASEchocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA88.9 ml/m^2.6
p-value: 0.07Wilcoxon (Mann-Whitney)
Secondary

Echocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA

Right ventricular end-diastolic volume indexed to BSA\^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.

Time frame: Measured pre-stage II surgery, an average of 15 days pre-stage II surgery

Population: 181 and 214 patients remained in the MBTS and RVPAS groups at the time of the pre-Stage II echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.

ArmMeasureValue (MEDIAN)
MBTSEchocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA113.4 ml/m^2.6
RVPASEchocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA105.2 ml/m^2.6
p-value: 0.009Wilcoxon (Mann-Whitney)
Secondary

Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA

Right ventricular end-systolic volume indexed to BSA\^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.

Time frame: Measured pre-stage II surgery, an average of 15 days pre-stage II surgery

Population: 181 and 214 patients remained in the MBTS and RVPAS groups at the time of the pre-Stage II echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.

ArmMeasureValue (MEDIAN)
MBTSEchocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA63.2 ml/m^2.6
RVPASEchocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA57.9 ml/m^2.6
Comparison: Wilcoxon rank-sum testp-value: 0.004Wilcoxon (Mann-Whitney)
Secondary

Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA

Right ventricular end-systolic volume indexed to BSA\^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.

Time frame: Measured at 14 months of age

Population: 184 and 179 patients remained in the MBTS and RVPAS groups at the 14-months of age echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.

ArmMeasureValue (MEDIAN)
MBTSEchocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA45.4 ml/m^2.6
RVPASEchocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA50.5 ml/m^2.6
p-value: 0.1Wilcoxon (Mann-Whitney)
Secondary

Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA

Right ventricular end-systolic volume indexed to BSA. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.

Time frame: Measured post-Norwood, an average of 17 days post-Norwood

Population: 241 and 239 patients remained in the MBTS and RVPAS groups at the time of the post-Norwood echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.

ArmMeasureValue (MEDIAN)
MBTSEchocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA50.1 ml/m^2.6
RVPASEchocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA44.2 ml/m^2.6
p-value: 0.001Wilcoxon (Mann-Whitney)
Secondary

Proportion of Deaths or Heart Transplants Over Time From Randomization to the End of the Trial

This secondary outcome was the proportion of deaths or cardiac transplantation over time from randomization to the end of the trial.

Time frame: From Randomization to the End of the Trial, an average of 32 months

ArmMeasureValue (NUMBER)
MBTSProportion of Deaths or Heart Transplants Over Time From Randomization to the End of the Trial107 Participants
RVPASProportion of Deaths or Heart Transplants Over Time From Randomization to the End of the Trial88 Participants
p-value: 0.06Log Rank
Secondary

Unintended Cardiovascular Interventional Procedures

Unintended cardiovascular procedures included balloon dilation of the shunt or branch pulmonary arteries, stent placement in the shunt or branch pulmonary arteries, shunt revision, crossover between MBTS and RVPAS shunt, balloon dilation, stent placement or surgical revisions of the neo-aorta, and pulmonary artery reconstructions, other than those undertaken as a standard component of the stage II procedure. The number of cardiovascular procedures was analyzed; trial participants may have had more than one unintended cardiovascular. procedure.

Time frame: From Randomization to 12 months

ArmMeasureValue (NUMBER)
MBTSUnintended Cardiovascular Interventional Procedures192 procedures
RVPASUnintended Cardiovascular Interventional Procedures252 procedures
p-value: 0.003Poisson regression

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026